Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H12FN3 |
| Molar mass | 265.291 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ a b Martinez A, Gil C (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
- ^ Macor JE (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
- ^ Fox SH, Brotchie JM (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
- ^ "Dipraglurant-ER for dystonia". Addex Therapeutics. Archived from the original on 2014-12-28. Retrieved 2014-12-28.
External links
edit- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics Archived 2014-12-28 at the Wayback Machine
- Dipraglurant-ER for dystonia - Addex Therapeutics Archived 2014-12-28 at the Wayback Machine
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |